New preclinical guidelines on drug effects on ventricular repolarization: safety pharmacology comes of age.
Kinter
Lewis B
LB
Safety Assessment U.S., Development, AstraZeneca Pharmaceuticals, Wilmington, DE 19850-5437, USA. lewis.kinter@astrazeneca.com
Siegl
Peter K S
PK
Bass
Alan S
AS
D000818:Animals; D015415:Biomarkers; D004353:Drug Evaluation, Preclinical / Q000592:standards*; D004562:Electrocardiography / Q000187:drug effects*; D017408:Guidelines as Topic; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced*; D018570:Risk Assessment; D012449:Safety / Q000592:standards; D016276:Ventricular Function
D015415:Biomarkers